Due to their efficacy in reducing relapses and lessening disability progression, anti-CD20 B-cell-depleting therapies are currently used in MS clinical practice and further support the rationale of blocking B-cell functions via BTK inhibition. Here, BTK is linked to myeloid sarcoma.